BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biohaven readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biohaven's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06443463-8940@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opakalim: Phase 2 readout est. (NCT06443463)
DESCRIPTION:Opakalim\, phase 2\, Epilepsy.\nStudy: Long-term Safety and Tol
 erability of BHV-7000\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/opakalim#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06443463
URL:https://assetmemo.bio/drug/opakalim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132893-8940@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opakalim: Phase 2/3 readout est. (NCT06132893)
DESCRIPTION:Opakalim\, phase 2/3\, Epilepsy.\nStudy: A Study to Determine i
 f BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epi
 lepsy\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/opakalim#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06132893
URL:https://assetmemo.bio/drug/opakalim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976268-1604@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BHV-8000: Phase 2/3 readout est. (NCT06976268)
DESCRIPTION:BHV-8000\, phase 2/3\, Parkinson's Disease.\nStudy: A Study to 
 Determine if BHV-8000 is Effective\, Safe and Tolerable as a Treatment for
  Adults Living With Early Parkinson's Disease\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bhv-8
 000#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06976268
URL:https://assetmemo.bio/drug/bhv-8000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642050-901@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BHV-1400: Phase 3 readout est. (NCT07642050)
DESCRIPTION:BHV-1400\, phase 3\, Chronic Kidney Disease.\nStudy: A Study to
  Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropath
 y\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bhv-1400#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07642050
URL:https://assetmemo.bio/drug/bhv-1400#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
